NASDAQ:AVDL

Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

$9.28

-0.72 (-7.20%)

(As of 12/2/2022 12:00 AM ET)

Add

Compare

Today's Range: $8.81
▼
$10.00
50-Day Range: $4.72
▼
$10.00
52-Week Range: $1.05
▼
$10.02

Volume: 957,772 shs
Average Volume: 919,999 shs
Market Capitalization: $573.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.71

Avadel Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 15.5% Upside
$10.71 Price Target
Short Interest: Bearish
7.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.83
Based on 12 Articles This Week
Insider Trading: Acquiring Shares
$39,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.99) to ($0.89) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

703rd out of 1,034 stocks

Pharmaceutical Preparations Industry

340th out of 502 stocks

2.4

Analyst's Opinion

Consensus Rating
Avadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.71, Avadel Pharmaceuticals has a forecasted upside of 15.5% from its current price of $9.28.
Amount of Analyst Coverage
Avadel Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.03% of the float of Avadel Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in Avadel Pharmaceuticals has recently decreased by 0.99%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Avadel Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Avadel Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVDL.

3.8

News and Social Media Coverage

News Sentiment
Avadel Pharmaceuticals has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Avadel Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
10 people have searched for AVDL on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.
MarketBeat Follows
5 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avadel Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $39,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.20% of the stock of Avadel Pharmaceuticals is held by insiders.
Percentage Held by Institutions
63.01% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($1.99) to ($0.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avadel Pharmaceuticals is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avadel Pharmaceuticals is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Avadel Pharmaceuticals (NASDAQ:AVDL) Stock

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

December 4, 2022 | americanbankingnews.com

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Expected to Post FY2025 Earnings of $1.59 Per Share

December 2, 2022 | americanbankingnews.com

Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Gap Up on Insider Buying Activity

December 2, 2022 | americanbankingnews.com

Jefferies Financial Group Upgrades Avadel Pharmaceuticals (NASDAQ:AVDL) to "Buy"

November 26, 2022 | finance.yahoo.com

Avadel Pharmaceuticals plc (NASDAQ:AVDL) insiders placed bullish bets worth US$677k in the last 12 months

November 26, 2022 | americanbankingnews.com

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Given Average Rating of "Moderate Buy" by Brokerages

November 25, 2022 | americanbankingnews.com

Oppenheimer Weighs in on Avadel Pharmaceuticals plc's Q2 2023 Earnings (NASDAQ:AVDL)

November 24, 2022 | benzinga.com

156K Reasons To Be Bullish On Avadel Pharmaceuticals Stock

November 24, 2022 | americanbankingnews.com

Avadel Pharmaceuticals (NASDAQ:AVDL) Price Target Raised to $9.00 at Needham & Company LLC

November 18, 2022 | benzinga.com

Avadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA's Orange Book

November 18, 2022 | seekingalpha.com

Avadel Pharmaceuticals jumps on patent win in dispute with Jazz Pharma (update)

November 18, 2022 | finance.yahoo.com

Avadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA’s Orange Book

November 15, 2022 | seekingalpha.com

Jazz Pharmaceuticals: Q3 Results, Pipeline Cleanup, And An Unhappy FTC

November 14, 2022 | msn.com

European ADRs Continue to Trend Higher in Monday Trading

November 12, 2022 | seekingalpha.com

Avadel at eight-month high as FTC comments raise prospects for lead drug

November 10, 2022 | markets.businessinsider.com

Needham Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)

November 10, 2022 | finance.yahoo.com

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

November 9, 2022 | finanznachrichten.de

Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 9, 2022 | finance.yahoo.com

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 8, 2022 | finance.yahoo.com

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

November 2, 2022 | finance.yahoo.com

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9

October 24, 2022 | finance.yahoo.com

Avadel Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022

October 16, 2022 | finance.yahoo.com

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is definitely on the radar of institutional investors who own 39% of the company

September 22, 2022 | finance.yahoo.com

Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

August 25, 2022 | seekingalpha.com

Avadel gains as judge delays hearing on patent dispute with Jazz Pharma

August 10, 2022 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Avadel Pharmaceuticals

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Company Calendar

Last Earnings: 11/08/2021
Today: 12/04/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/16/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AVDL
CUSIP: N/A
CIK: 1012477
Web: www.avadel.com
Phone: (531) 485-1200
Fax: 353-1526-1077
Employees: 66
Year Founded: 2015

Price Target and Rating

Average Stock Price Forecast: $10.71
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +15.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-77,330,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -334.88%
Return on Assets: -51.04%

Debt

Debt-to-Equity Ratio: 2.11
Current Ratio: 2.73
Quick Ratio: 2.73

Sales & Book Value

Annual Sales: $22.33 million
Price / Sales: 25.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.20) per share
Price / Book: -46.40

Miscellaneous

Outstanding Shares: 61,780,000
Free Float: 59,802,000
Market Cap: $573.32 million
Optionable: Optionable
Beta: 1.62

Social Links

Key Executives

Mr. Gregory J. Divis Jr. (Age 55)
CEO & Director
Comp: $862.59k

Mr. Thomas S. McHugh (Age 57)
Sr. VP & CFO
Comp: $550k

Mr. Richard Kim (Age 53)
Chief Commercial Officer
Comp: $596.3k

Mr. Jerad G. Seurer
Gen. Counsel & Company Sec.

Mr. Gregory J. Davis (Age 57)
VP of Corp. and Bus. Devel.

Mr. Mark W. Elrod
VP of Sales

Ms. Angie Woods
VP of People & Culture

Mr. Christian Kalita Pharm.D
Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs

Mr. Steven G. Sullivan (Age 57)
VP of Sales & Marketing and Head of Commercial Operations

Dr. Jordan S. Dubow M.D. (Age 44)
Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVDL Stock - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings or view top-rated stocks.
What is Avadel Pharmaceuticals' stock price forecast for 2023?: 6 Wall Street analysts have issued twelve-month target prices for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $5.00 to $13.00. On average, they predict the company's stock price to reach $10.71 in the next year. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts.
How have AVDL shares performed in 2022?: Avadel Pharmaceuticals' stock was trading at $8.08 at the beginning of 2022. Since then, AVDL stock has increased by 14.9% and is now trading at $9.28.
View the best growth stocks for 2022 here.
When is Avadel Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our AVDL earnings forecast.
How were Avadel Pharmaceuticals' earnings last quarter?: Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.38). During the same quarter in the prior year, the company posted ($0.20) earnings per share.

What other stocks do shareholders of Avadel Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).
What is Avadel Pharmaceuticals' stock symbol?: Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."
Who are Avadel Pharmaceuticals' major shareholders?: Avadel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Gendell Jeffrey L (8.00%), Brandes Investment Partners LP (4.52%), Renaissance Technologies LLC (1.32%), Citadel Advisors LLC (0.00%), Modera Wealth Management LLC (0.91%) and Two Sigma Investments LP (0.38%). Insiders that own company stock include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, Sandra L Hatten and Thomas S Mchugh.
View institutional ownership trends.
How do I buy shares of Avadel Pharmaceuticals?: Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Avadel Pharmaceuticals' stock price today?: One share of AVDL stock can currently be purchased for approximately $9.28.
How much money does Avadel Pharmaceuticals make?: Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $573.32 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.
How can I contact Avadel Pharmaceuticals?: Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 485-1200, via email at investors@avadel.com, or via fax at 353-1526-1077.

This page (NASDAQ:AVDL) was last updated on 12/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial